New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Rocket Pharmaceuticals, Inc.
RCKT
Shape
US Flag

NASDAQ

Unprofitable

Unprofitable

2B

Biotechnology

Next Earning date - 04 Nov 2024

2B

Biotechnology

Next Earning date - 04 Nov 2024

17.70USD
Shape0.08 ( 0.45%)
favorite-chart

Relative Strenght

21
favorite-chart

Volume Buzz

-30%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

46%

Quote Panel

Shape
Updated October 23, 2024
1W -4.02 % 1M -3.28 % 3M -29.32 % 1Y -0.90 %

Key Metrics

Shape
  • Market Cap

    1.61B


  • Shares Outstanding

    90.98M


  • Share in Float

    83.82M


  • Dividende

    0


  • Earning Date

    04 Nov 2024


  • Price Target

    17.7


  • Average Volume

    862796


  • Beta

    1.087


  • Range

    15.975-32.525


  • Industry

    Biotechnology


  • Website

    https://rocketpharma.com


  • Sector

    Healthcare


Fundamentals

Shape

N/A

P/E Ratio

156.77x

P/S Ratio

4.33x

P/B Ratio

0.1

Debt/Equity

-2456.0%

Net Margin

$-2.8

EPS

How RCKT compares to sector?

P/E Ratio

Relative Strength

Shape

RCKT

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$59M

ShapeNaN%

2025-Revenue

$2.64

Shape-256%

2025-EPS

0

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Goldman Sachs

initialise

Previous: Not converted

2024-04-02

Now: Neutral

Morgan Stanley

initialise

Previous: Not converted

2023-02-01

Now: Overweight

Raymond James

initialise

Previous: Not converted

2022-07-08

Now: Outperform

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

N/A

-0.87
vs -0.79

Q4.22

arrow
arrow

N/A

-0.92
vs -0.69

Q1.23

arrow
arrow

N/A

-0.73
vs -0.67

Q2.23

arrow
arrow

N/A

-0.82
vs -0.83

Q3.23

arrow
arrow

N/A

-0.75
vs -0.87

Q4.23

arrow
arrow

N/A

-0.64
vs -0.92

Q1.24

arrow
arrow

N/A

-0.66
vs -0.73

Q2.24

arrow
arrow

N/A

-0.74
vs -0.82

Q3.24

arrow
arrow

N/A

-0.75
vs -0.75

Q4.24

arrow
arrow

N/A

-0.76
vs -0.64

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

NA

NA  vs NA

Q4.22

arrow
arrow

NA

NA  vs NA

Q1.23

arrow
arrow

NA

NA  vs NA

Q2.23

arrow
arrow

NA

NA  vs NA

Q3.23

arrow
arrow

NA

NA  vs NA

Q4.23

arrow
arrow

NA

10.3M  vs NA

Q1.24

arrow
arrow

NA

NA  vs NA

Q2.24

arrow
arrow

NA

NA  vs NA

Q3.24

arrow
arrow

NA

564.3K  vs NA

Q4.24

arrow
arrow

+8%

11.1M  vs 10.3M

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

-16%

-0.16
vs -0.14

Q4.22

arrow
arrow

-13%

-0.13
vs -0.16

Q1.23

arrow
arrow

-12%

-0.12
vs -0.13

Q2.23

arrow
arrow

-16%

-0.16
vs -0.12

Q3.23

arrow
arrow

-11%

-0.11
vs -0.16

Q4.23

arrow
arrow

-12%

-0.12
vs -0.11

Q1.24

arrow
arrow

-14%

-0.14
vs -0.12

Q2.24

arrow
arrow

-18%

-0.18
vs -0.14

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

167

167
vs 147

14%

Q4.22

arrow
arrow

172

172
vs 167

3%

Q1.23

arrow
arrow

166

166
vs 172

-3%

Q2.23

arrow
arrow

166

166
vs 166

NA

Q3.23

arrow
arrow

186

186
vs 166

12%

Q4.23

arrow
arrow

208

208
vs 186

12%

Q1.24

arrow
arrow

198

198
vs 208

-5%

Q2.24

arrow
arrow

183

183
vs 198

-8%

Earnings Growth

Latest News